Brought to you by 
Pfizer teams up with Sangamo in hemophilia A
26 Dec 2019
Executive Summary
In a potential $545mm deal, Sangamo Therapeutics Inc. is partnering its hemophilia gene therapy programs, including Phase I-ready SB525, with Pfizer Inc.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com